Eliquis (apixaban) is taken as a tablet by mouth, typically twice a day, roughly 12 hours apart, with or without food. The standard dose for most people with atrial fibrillation is 5 mg twice daily, though some patients qualify for a lower 2.5 mg twice-daily dose based on age, weight, and kidney function. While the basics sound simple, a surprising number of practical questions come up once you start taking it: what happens if you miss a dose, whether you can crush the tablet, how kidney or liver problems change the picture, and what common painkillers you should avoid.
Standard Doses and What They Treat
Eliquis is approved for several conditions, and the dose depends on why you’re taking it. For stroke prevention in atrial fibrillation, the standard dose is 5 mg twice daily. In its landmark trial against warfarin, that 5 mg twice-daily dose reduced stroke, systemic embolism, mortality, and major bleeding compared with the older drug.1PubMed. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper The same drug is also used to treat and prevent blood clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism), though the dosing schedule differs in the first week of treatment, when a higher loading dose is used before stepping down.
If you’ve just had hip or knee replacement surgery, Eliquis is prescribed at 2.5 mg twice daily to prevent post-surgical clots. That lower prophylactic dose is distinct from the reduced dose some atrial fibrillation patients receive, which also happens to be 2.5 mg twice daily but for entirely different reasons.
Who Gets the Reduced Dose
Not everyone with atrial fibrillation takes 5 mg. The dose drops to 2.5 mg twice daily if you meet at least two of three criteria: age 80 or older, body weight 60 kg (about 132 pounds) or less, and a serum creatinine level of 1.5 mg/dL or higher.2PubMed. Validity of different dose reduction criteria for apixaban Dose adjustments are also considered for moderate kidney dysfunction and certain drug interactions.3The American Journal of Medicine. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
This is one area where mistakes happen. Some prescribers reduce the dose when a patient only meets one of the three criteria, and others keep patients on the full dose when they actually qualify for reduction. Both errors matter: taking too little can leave you underprotected against stroke, while taking more than you need raises bleeding risk. If you’re unsure whether your dose is right, the conversation with your doctor is worth having, especially if your weight, age, or kidney function has changed since you started.
Why Twice a Day Matters
Eliquis is absorbed quickly, reaching its peak blood level about three to four hours after you swallow it, and its half-life is roughly 12 hours.4PubMed Central. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review That 12-hour half-life is why you take it twice a day: it keeps the drug level steady enough to suppress clotting around the clock. Spacing your doses about 12 hours apart, say morning and evening, is the simplest way to maintain that consistency.
If you take both doses too close together, you get a spike followed by a trough where the drug level drops below effective levels. If you stretch the interval to 16 or 18 hours, you also spend part of the day less protected. Perfection isn’t required, but aiming for a consistent 12-hour rhythm gives you the best balance between effectiveness and safety.
Food, Crushing, and Swallowing Difficulties
One of the more convenient things about Eliquis is that food doesn’t meaningfully change how much of the drug your body absorbs. Even a high-fat, high-calorie meal only reduced the peak blood level by about 15% and overall exposure by about 20%, and researchers considered neither reduction clinically significant.5Clinical Therapeutics. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults So you can take it with breakfast, on an empty stomach at bedtime, or anywhere in between. No meal planning required.
If you have trouble swallowing tablets, you have options. Crushed Eliquis mixed into water meets the same bioequivalence standards as the intact tablet. Crushed tablet mixed with applesauce showed slightly lower absorption, but again, the reduction wasn’t considered clinically meaningful.5Clinical Therapeutics. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults For patients with feeding tubes, apixaban can be given as a crushed tablet suspension or a liquid solution through a nasogastric tube, with comparable absorption when flushed with a dextrose solution or infant formula.6Clinical Therapeutics. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects The one combination that fell short was a nutritional supplement flush through a nasogastric tube, which lowered absorption enough to miss the bioequivalence threshold.
What to Do When You Miss a Dose
The general guidance is straightforward: if you remember within a few hours, take the missed dose as soon as you can, then go back to your regular schedule. If it’s already nearly time for your next dose, skip the missed one and take the next one on time. Never double up to “catch up,” because stacking two doses raises your bleeding risk without providing meaningful extra protection.
The reason this works is Eliquis’s relatively short half-life. Missing a single dose leaves a gap of perhaps 18 to 24 hours where your drug levels are lower than ideal, which is not great but also not catastrophic for most patients. What’s more dangerous is a pattern of missed doses, where you’re routinely leaving yourself unprotected for stretches of the day. If you’re frequently forgetting the evening dose, setting a phone alarm or pairing the dose with a consistent daily habit like brushing your teeth can help.
Over-the-Counter Painkillers and Eliquis
This is where a lot of people run into trouble without realizing it. Common over-the-counter anti-inflammatory drugs like ibuprofen and naproxen carry their own bleeding risk and can amplify the bleeding effect of Eliquis when combined. A survey of patients on apixaban found that roughly two-thirds were either unsure or wrong about the potential for increased bleeding when combining these painkillers with their anticoagulant.7PubMed Central. Prevalence and Knowledge of Potential Interactions Between Over-the-Counter Products and Apixaban
Acetaminophen (Tylenol) is generally the safer choice for occasional pain relief while on Eliquis, since it doesn’t affect platelet function the way anti-inflammatory drugs do. If you need something stronger or more targeted, that’s a conversation for your prescriber. The key point is that just because a painkiller is available without a prescription doesn’t mean it’s harmless alongside a blood thinner.
Kidney Function and Dosing
Eliquis has one of the more forgiving kidney profiles among blood thinners. Only about 27% of the drug is cleared through the kidneys, with the rest eliminated through the liver, bile, and the gut.4PubMed Central. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review That means even people with significant kidney impairment can often use it, though the dose may need adjustment.
For patients with advanced kidney disease, including those on dialysis, the picture gets more complex. Eliquis is barely removed during a four-hour dialysis session, with studies reporting only about 4 to 14% clearance, partly because the drug is highly bound to proteins in the blood.8PubMed Central. Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data Pharmacokinetic studies suggest that a 2.5 mg twice-daily dose in patients with kidney failure produces blood levels similar to what 5 mg produces in people with normal kidneys, while 5 mg in kidney failure patients resulted in roughly three-fold higher exposure than intended.9PubMed. Apixaban Dose Selection in Kidney Failure: Reconciling Pharmacokinetics and Clinical Outcomes
Despite that pharmacokinetic logic favoring the lower dose, some observational studies have found that the higher dose was associated with lower mortality in dialysis patients, while one study found the 5 mg dose carried a 63% higher bleeding rate with no reduction in stroke.9PubMed. Apixaban Dose Selection in Kidney Failure: Reconciling Pharmacokinetics and Clinical Outcomes The two randomized trials that tried to settle this question were both terminated early and remain too small to give a definitive answer. This is an area where the evidence is genuinely unsettled, and the dose for dialysis patients tends to be an individualized decision. Compared with warfarin in advanced kidney disease, apixaban showed similar bleeding rates at three months but significantly less major bleeding between six and twelve months.10PubMed. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease
Liver Disease and Eliquis
About a quarter of Eliquis is processed through the liver. In people with mild to moderate liver disease, the drug’s blood levels don’t change much: studies show that moderate liver impairment raises overall drug exposure by only about 9%, a negligible amount.11PubMed. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment That makes Eliquis one of the better-tolerated options in this class for patients with liver problems. The labeling allows its use, with caution, in mild and moderate liver disease but does not recommend it for severe liver impairment, especially when the liver disease itself is already causing bleeding problems.12PubMed Central. Drug Use Evaluation of Direct Oral Anticoagulants in Patients With Advanced Cirrhosis
Early data suggest that direct oral anticoagulants may be safe in mild to moderate chronic liver disease, though researchers have noted that more frequent monitoring is warranted and that larger trials are still needed.13PubMed. Direct Oral Anticoagulants in Chronic Liver Disease If you have liver cirrhosis and are on Eliquis, your doctor should be checking in on liver function more regularly than they would for a typical patient.
Stopping Before Surgery or Procedures
One of the most common real-world questions about Eliquis is when to stop taking it before a procedure. The timing depends on how much bleeding risk the procedure carries and how well your kidneys work.
For low to moderate bleeding risk procedures, stopping Eliquis one day before and restarting one day after is typical. For high bleeding risk procedures, stopping two days before and restarting two days after is the more common approach. With that strategy, rates of blood clots afterward are low, around 0.2 to 0.4%, and major bleeding sits at roughly 1 to 2%.14JAMA. Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review For minimal-risk procedures like simple dental work or cataract surgery, some guidelines say you can continue Eliquis or simply skip it on the day of the procedure.
Kidney function extends these timelines. If your kidneys are moderately impaired, stopping 72 hours before a high bleeding risk procedure is recommended, and in cases of severe kidney impairment, that window stretches to 96 hours.15PubMed Central. Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review The reason is that reduced kidney function slows the drug’s clearance, so you need extra lead time for it to leave your system. Never stop or restart Eliquis around a procedure without specific guidance from your surgical and prescribing teams.
The Twice-Daily Adherence Challenge
Here’s where the honest conversation about Eliquis gets interesting. Taking any medication twice a day is harder than taking it once a day, and the research backs that up. A systematic review involving nearly a million patients found that once-daily dosing regimens had significantly higher adherence and persistence rates than twice-daily ones. Adherence favored once-daily in over half of comparisons, while only about 12% of comparisons favored twice-daily.16PubMed Central. Adherence and persistence with direct oral anticoagulants by dose regimen: A systematic review
Real-world data from the Netherlands, Italy, and Germany showed that adherence rates for once-daily and twice-daily direct oral anticoagulants were fairly close in some countries (93% versus 90% in the Netherlands) but diverged more in others (77% versus 58% in Germany).17PubMed Central. Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany Persistence at one year, meaning still taking the medication at all, varied widely by country and dosing frequency.
None of this means Eliquis is the wrong choice. Its twice-daily schedule is a trade-off for its clinical profile, which showed advantages over warfarin in bleeding and stroke outcomes. But if you know you’re bad at remembering a second daily dose, acknowledge that upfront. Pill organizers, phone alarms, and pairing the dose with a routine activity all make a measurable difference. The drug can only protect you if it’s actually in your bloodstream.
Extreme Body Weight
For people at either end of the weight spectrum, a natural question is whether standard dosing still works. The pharmacokinetic data show that drug exposure is about 23% lower in high-weight individuals compared with a reference group, likely because of increased non-kidney elimination pathways.18PubMed Central. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data That sounds concerning on paper, but the clinical data tell a reassuring story: in a large analysis of patients across the weight spectrum, including those above 120 kg, apixaban remained effective and safe compared with warfarin. The drug’s advantages in reducing stroke and major bleeding held across weight groups.19PubMed. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight In patients with low to normal weight, the reductions in major bleeding compared with warfarin were actually even more pronounced.
So while some other blood thinners carry more cautious labeling for very heavy patients, Eliquis appears to work well across the full range of body weights without a dose change based on weight alone. Weight is one of the three dose-reduction criteria, but only at the low end (60 kg or less) and only in combination with at least one other criterion.
Pregnancy, Breastfeeding, and Eliquis
Direct oral anticoagulants, including Eliquis, are generally avoided during pregnancy. The main concern is that there is very little human safety data, and animal studies have raised flags about reproductive toxicity. If you need anticoagulation during pregnancy, your doctor will almost certainly switch you to a different type of blood thinner.
Breastfeeding presents its own issue. A pharmacokinetic modeling study found that apixaban transfers into breast milk at substantially higher levels than rivaroxaban, another drug in the same class. The estimated infant plasma exposure from a breastfeeding mother taking apixaban 5 mg twice daily was roughly eight times higher than from a mother taking rivaroxaban 20 mg once daily.20Journal of Thrombosis and Haemostasis. Considerations of safety for women prescribed apixaban or rivaroxaban who breastfeed—a physiologically based pharmacokinetic analysis The researchers concluded that apixaban would not be a suitable agent for breastfeeding women during the postnatal period. If you’re breastfeeding and need an anticoagulant, this is a specific reason to discuss alternatives.
If There Is an Emergency
One of the historical concerns about newer blood thinners was the lack of an antidote in case of serious bleeding or emergency surgery. For Eliquis, that gap has been filled. Andexanet alfa (brand name Andexxa) received FDA approval specifically for urgent reversal of the anticoagulant effect of apixaban and rivaroxaban.21JAMA. Andexxa—An Antidote for Apixaban and Rivaroxaban It works by acting as a decoy for the drug, binding it up so it can no longer block clotting. The reversal agent is available in hospitals and emergency departments, though it’s expensive and reserved for life-threatening situations.
Knowing that an antidote exists can ease the anxiety some people feel about being on a blood thinner, especially before travel or physically risky activities. It’s worth noting, though, that serious bleeding events on Eliquis are uncommon. The existence of a reversal agent is a safety net, not something most patients will ever need.
Switching To or From Other Blood Thinners
Transitions between anticoagulants happen frequently in practice: moving from warfarin to Eliquis, switching between different direct oral anticoagulants, or bridging with injectable heparin around a hospitalization. The goal during any switch is to avoid both a gap in protection (which risks clots) and overlap between two drugs (which risks bleeding). The timing of these transitions depends on which drugs are involved and how they are cleared from the body. Your prescriber will typically base the transition schedule on the protocols established in the original clinical trials and the drug’s prescribing information. This is not a transition to manage on your own; the timing is precise enough that even a one-day error in either direction matters.
Cost and Generic Availability
Eliquis has been one of the best-selling prescription drugs worldwide, and its cost has been a barrier for some patients. In the United States, generic apixaban became available in 2026, which has begun to improve affordability. Globally, the affordability of direct oral anticoagulants remains a concern, and access varies sharply by country. Strategies like government price negotiation, pooled procurement, and expanded use of generics can increase access, but without reimbursement through national health budgets, many patients remain unable to afford them.22PubMed Central. Global access to affordable direct oral anticoagulants
If cost is a factor, ask your pharmacy about generic availability, manufacturer discount programs, and whether mail-order pharmacies offer a lower price. Skipping doses or splitting pills to stretch a supply is a genuinely dangerous strategy with an anticoagulant. A day without adequate blood-thinner coverage is a day your stroke risk goes back up.